CCN2 and neoplasm: Over expression of CTGF is associated with poor clinical outcomes including advanced disease with larger tumor size, worse metastasis, decreased treatment response in many cancers such as but not limited to breast, gastric, esophageal, pancreatic and prostate cancer (79, 80).